Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rhabdomyosarcoma - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Rhabdomyosarcoma - Pipeline Review, H1 2015’, provides an overview of the Rhabdomyosarcoma’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rhabdomyosarcoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rhabdomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Rhabdomyosarcoma Overview 6 Therapeutics Development 7 Pipeline Products for Rhabdomyosarcoma - Overview 7 Pipeline Products for Rhabdomyosarcoma - Comparative Analysis 8 Rhabdomyosarcoma - Therapeutics under Development by Companies 9 Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes 10 Rhabdomyosarcoma - Pipeline Products Glance 11 Clinical Stage Products 11 Rhabdomyosarcoma - Products under Development by Companies 12 Rhabdomyosarcoma - Products under Investigation by Universities/Institutes 13 Rhabdomyosarcoma - Companies Involved in Therapeutics Development 14 Bellicum Pharmaceuticals, Inc. 14 Boehringer Ingelheim GmbH 15 Celgene Corporation 16 Eisai Co., Ltd. 17 GlaxoSmithKline plc 18 Merrimack Pharmaceuticals, Inc. 19 Neotropix, Inc. 20 Novartis AG 21 Rhabdomyosarcoma - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 afatinib - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 celyvir - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 E-7438 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 everolimus - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 irinotecan sucrosofate liposomal - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 NTX-010 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 paclitaxel albumin bound - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 pazopanib hydrochloride - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Rhabdomyosarcoma - Recent Pipeline Updates 58 Rhabdomyosarcoma - Dormant Projects 84 Rhabdomyosarcoma - Discontinued Products 85 Appendix 86 Methodology 86 Coverage 86 Secondary Research 86 Primary Research 86 Expert Panel Validation 86 Contact Us 86 Disclaimer 87
List of Tables Number of Products under Development for Rhabdomyosarcoma, H1 2015 7 Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Products under Investigation by Universities/Institutes, H1 2015 13 Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 14 Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 15 Rhabdomyosarcoma - Pipeline by Celgene Corporation, H1 2015 16 Rhabdomyosarcoma - Pipeline by Eisai Co., Ltd., H1 2015 17 Rhabdomyosarcoma - Pipeline by GlaxoSmithKline plc, H1 2015 18 Rhabdomyosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 19 Rhabdomyosarcoma - Pipeline by Neotropix, Inc., H1 2015 20 Rhabdomyosarcoma - Pipeline by Novartis AG, H1 2015 21 Assessment by Monotherapy Products, H1 2015 22 Number of Products by Stage and Target, H1 2015 24 Number of Products by Stage and Mechanism of Action, H1 2015 26 Number of Products by Stage and Route of Administration, H1 2015 28 Number of Products by Stage and Molecule Type, H1 2015 30 Rhabdomyosarcoma Therapeutics - Recent Pipeline Updates, H1 2015 58 Rhabdomyosarcoma - Dormant Projects, H1 2015 84 Rhabdomyosarcoma - Discontinued Products, H1 2015 85
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.